



Part B Provider-Administered Precertification Drug List

Effective May 1, 2024

Patrius Health includes the following drugs in the Blue Advantage Part B Provider-Administered Drug Precertification Program. Precertification for these provider-administered drugs is required when administered in a provider's office, outpatient facility, or home health setting. Treatments indicated as Gene Therapy/Cellular Immunotherapy (+) require precertification when administered in any place of treatment.

Abecma+	Cinryze	Fulphila	Lamzede	Polivy
Abraxane	Cinvanti	Fulvestrant	Lemtrada	Pombiliti
Actemra IV	Columvi	Fusilev	Lenmeldy	Portrazza
Adakveo	Cortrophin	Fyarro	Leqembi	Poteligeo
Adcetris	Cosentyx_IV	Fylnetra	Leqvio	Privigen
Adstiladrin+	Crysvita	Gamifant	Leukine	Probuphine
Aduhelm	Cutaquig	Gammagard	Libtayo	Procrit
Adzynma	Cuvitru	Gammaked	Loqtorz	Prolia
Akynzeo IV	Cyramza	Gammaplex	Lucentis	Provenge
Aldurazyme	Danyelza	Gamunex-C	Lumizyme	Qalsody
Alimta	Darzalex	Gazyva	Lumoxiti	Radicava
Aloxi	Darzalex Faspro	Gel-One	Lunsumio	Reblozyl
Alyglo	Daxxify	Gelsyn-3	Luxturna+	Releuko
Alymsys	Dextenza	Genvisc	Lyfgenia+	Retacrit
Amondys 45	Durolane	Givlaari	Macugen	Rituxan Hycela
Amtagvi	Dysport	Granix	Margenza	Rituxan IV
Amvuttra	Elahere	Hemgenix+	Mepsevii	Rivfloza
Aphexda	Elaprase	Herceptin	Monjuvi	Roctavian+
Arzerra	Elelyso	Herceptin Hylecta	Monovisc	Rolvedon
Asceniv	Elevidys+	Herzuma	Mylotarg	Ruconest
Avastin*	Elfabrio	Hizentra	Myobloc	Rybrevent
Avzivi	Elitek	Hyalgan	Naglazyme	Rystiggo
Bavencio	Elrexio	Hymovis	Neupogen	Ryzneuta
Belrapzo	Elzonris	Hyqvia	Nexviazyme	Saphnelo
Bendamustine	Emend	Ilaris	Nplate	Sarclisa
Bendeka	Empliciti	Ilumya	Nucala	Scenesse
Benlysta IV	Enhertu	Imfinzi	Nulibry	Simponi Aria
Beovu	Enjaymo	Imjudo	Ocrevus	Skyrizi IV
Berinert	Entyvio	Imlygic	Octagam	Skysona+
Besponsa	Epkinly	Inflectra	Ogivri	Sodium Hyaluronate
Bivigam	Epogen	Ixempra	OmvoH	Soliris
Blincyto	Erbitux	Izervay	Onpattro	Spevigo
bortezomib	Euflexxa	Jelmyto	Ontruzant	Spinraza
Botox	Evkeeza	Jemperli	Opdivo	Spravato
Breyanzi+	Evomela	Jubbonti	Opdualag	Stelara IV
Brineura	Exondys 51	Kadcyla	Orencia IV	Stimufend
Briumvi	Eylea	Kalbitor	Oxlumo	Sublocade
Byooviz	Eylea HD	Kanuma	Paclitaxel Protein-Bound	Supartz
Carvykti+	Fabrazyme	Keytruda	Padcev	Sustol
Casgevy+	Fasenra	Khapzory	Panzyga	Susvimo
Cerezyme	Faslodex	Kimtrak	Pemfexy	Syfovre
Cimerli	Flebogamma	Krystexxa	Pemtrexed	Sylvant
Cimzia	Focinvez	Kymriah+	Perjeta	Synjoynt
Cinqair	fosaprepitant	Kyprolis	Phesgo	Talvey

Tecartus+	Trodelyv	Velcade	Vyxeos	Yescarta+
Tecentriq	Trogarzo	Veopoz	Vyvgart Hytrulo	Yondelis
Tecvayli	Tyenne	Viltepso	Wezlana	Zaltrap
Tepezza	Tyruko	Vimizim	Winrevair	Zepzelca
Testopel	Tysabri	Visco-3	Wyost	Zoladex
Tevimbra	Tzield	Visudyne	Xembify	Zolgensma+
Tezspire	Udenyca	Vivimusta	Xenpozyme	Zynlonta
Tivdak	Ultomiris	Vivitrol	Xeomin	Zynteglo+
Tofidence	Uplizna	Vpriv	Xgeva	Zynyz
Treanda	Vabysmo	Vyepti	Xiaflex	
Trelstar Depot	Vantas	Vyjuvek+	Xipere	
Triluron	Vectibix	Vyondys-53	Xolair	
Trivisc	Vegzelma	Vyvgart	Yervoy	

Drug Additions

Effective January 1, 2024:

Adzynma
Loqtorz
Omvoh
Ryzneuta
Wezlana

Drug Deletions

Effective January 1, 2024:

Truxima

Drug Additions

Effective February 1, 2024:

Alyglo
Avzivi
Casgevy+
Lyfgenia+

Drug Additions

Effective April 1, 2024:

Amtagvi

Drug Additions

Effective May 1, 2024:

Jubbonti
Wyost
Tyenne
Tevimbra
Lenmeldy
Winrevair

*Precertification required for oncology uses only.

Product names are the property of their respective owners. This list is updated monthly and is subject to change without notice.

Online policies can be found by logging in to **myBlue Provider** and clicking on Blue Advantage Resources.